Recent Quotes (30 days)

You have no recent quotes
chg | %

GlaxoSmithKline plc news

   Watch this stock
Showing stories 1 - 10 of about 172   

Articles published

GSK 1,392.38 -20.12 (-1.42%)
price chart
1 Reason I Wouldn't Buy GlaxoSmithKline plc Today
GlaxoSmithKline remains stuck between a rock and a hard place as allegations of improper conduct spread across its global operations continue to grow.
GlaxoSmithKline plc Could Be Worth 1690p!
GlaxoSmithKline Investors in GlaxoSmithKline (LSE: GSK) have had a truly dismal 2014. Shares in the pharmaceutical company are down 12% since the turn of the year, with the FTSE 100 being flat over the same time period.
At What Price Would GlaxoSmithKline plc Be A Bargain Buy?
gsk Patience is one of the key attributes of a successful investor. The likes of US master Warren Buffett have been known to wait years for the right company at the right price.
3 Shares To Get Rich: GlaxoSmithKline plc, National Grid plc And Lloyds ...
Even though the FTSE 100 has pulled back in recent weeks and the future looks decidedly uncertain, in the long run investing in shares should pay off.
Related articles »  
GlaxoSmithKline plc Is The Ideal Dividend Investment
I've never quite been able to make up my mind about GlaxoSmithKline (LSE: GSK). It's one of the world's leading pharmaceutical companies, with perhaps the strongest drugs pipeline in pharma.
3 Stocks That May Positively Surprise You: SSE PLC, GlaxoSmithKline plc ...
Despite sector peers such as AstraZeneca and Shire trading on price to earnings (P/E) ratios that are in the high teens/early twenties, you may be surprised to find out that GlaxoSmithKline (LSE: GSK) trades on a P/E of just 12.3. That's even lower ...
Related articles »  
GlaxoSmithKline plc Beats AstraZeneca plc And Shire PLC In The ...
AstraZeneca Pharmaceuticals companies have been big in the news in recent months. Pfizer's bid for AstraZeneca (LSE: AZN) (NYSE: AZN.
3 Neil Woodford High-Yield Shares: GlaxoSmithKline plc, Centrica PLC and SSE ...
gsk Renowned fund manager Neil Woodford has been thrashing the market for a quarter of a century. Woodford is a very selective stockpicker.
Related articles »  
GlaxoSmithKline plc's Dividends Are Rising Nicely
Big pharmaceuticals companies like GlaxoSmithKline (LSE: GSK) (NYSE: GSK.US) have been relied on for decades to provide steady dividend income, and with the company having provided a 4.8% yield last year, it's not hard to see why.
Related articles »  
Will Pfizer Inc. Make A Bid For GlaxoSmithKline plc?
GlaxoSmithKline's (LSE: GSK) (NYSE: GSK.US) shares have slumped nearly 12%, year to date, a disappointing performance for investors.
Related articles »